Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pixu 3 decoction
- Development stage
- Unknown
- Lead developer
- Xiyuan Hospital
- Administration
- Oral
01
Overview
Pixu 3 decoction is a traditional Chinese medicine (TCM) formulation developed by Xiyuan Hospital, affiliated with the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of functional dyspepsia, a condition characterized by chronic indigestion without an obvious structural cause. The formulation is part of a "differential treatment of spleen" approach, where "Pixu" refers to Spleen Deficiency in TCM theory. It was evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 1 clinical trial (ChiCTR-TRC-13003200) alongside Pixu 1 and Pixu 2 decoctions to assess symptom relief in adult patients.
Beyond the preview
Go deeper on Pixu 3 decoction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pixu 3 decoction.